In February 2020, a report from FDA’s Office of Pharmaceutical Quality (OPQ) noted that, “Quite simply, the quality of our drug supply is better than ever before.” With some FDA inspections on hold, will the US drug supply maintain its quality standards? Plus, which new drug applications must now be filed as biologic license application?

	When referring to this article, please cite it as R. Peters, “Is There a “New Normal” for Drug Quality?" 

BioPharm International Regulatory Sourcebook and Reference

Audits and Inspections

Development

Quality/GMPs

Regulatory Authority Actions

Regulatory Filings and Submissions

Regulatory/GMP Compliance

Regulatory/GMP Compliance, Emerging Markets

Regulatory/GMP Compliance, Europe

BioPharm International-03-15-2020

With some FDA inspections on hold, will the US drug supply maintain its quality standards? 